LitAlert ~~ GeneLit.com

    • LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma.
    • Sato S, Gillette M, de Santiago PR, Kuhn E, Burgess M, Doucette K, Feng Y, Mendez-Dorantes C, Ippoliti PJ, Hobday S, Mitchell MA, Doberstein K, Gysler SM, Hirsch MS, Schwartz L, Birrer MJ, Skates SJ, Burns KH, Carr SA, Drapkin R.
    • Sci Rep. 2023 Jan 27;13(1):1537. doi: 10.1038/s41598-023-28840-5.
    • Inflammatory cytokines-enriched microenvironment plays key roles for the development of breast cancers.
    • Takeuchi Y, Gotoh N.
    • Cancer Sci. 2023 Jan 26. doi: 10.1111/cas.15734. Epub ahead of print.
    • Review
    • Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency.
    • Guantay L, Garro C, Siri S, Pansa MF, Ghidelli-Disse S, Paviolo N, Racca A, Nicotra V, Radu C, Bocco JL, Felice R, Jansson KH, Remlinger K, Amador A, Stronach E, Coleman K, Muelbaier M, Drewes G, Gloger I, Madauss K, García M, Gottifredi V, Soria G.
    • Drug Resist Updat. 2023 Jan 22;67:100932. doi: 10.1016/j.drup.2023.100932. Epub ahead of print.
    • PARP1 inhibitors induce pyroptosis via caspase 3-mediated gasdermin E cleavage.
    • Kim C, Wang XD, Jang S, Yu Y.
    • Biochem Biophys Res Commun. 2023 Jan 20;646:78-85. doi: 10.1016/j.bbrc.2023.01.055. Epub ahead of print.
    • Curcumin enhances the anti-cancer efficacy of paclitaxel in ovarian cancer by regulating the miR-9-5p/BRCA1 axis.
    • Liu Y, Shen Z, Zhu T, Lu W, Fu Y.
    • Front Pharmacol. 2023 Jan 10;13:1014933. doi: 10.3389/fphar.2022.1014933.